Arctic Vision Launches Upgraded iTEAR MuQin®: China's First Natural Tear Secretion Promoting Device for Dry Eye Therapy
Arctic Vison
Ophthalmic New Drug Developer
On May 21, 2024, Arctic Vison announced iTEAR Muqing.®The all-new upgraded version of the self-tear secretion stimulator has officially launched, bringing an innovative treatment solution of natural tears to a wide range of dry eye patients.
iTEAR Muqin®：
China's First Natural Tear Secretion Therapy for Dry Eye
iTEAR Muqing®It is a product that promotes self-improvement through external nasal nerve stimulation.Natural TearsSecreted Class II Medical Device. iTEAR Muqing®As the first product in China to improve dry eye symptoms by stimulating the external nasal nerve, and also the first natural tear secretion-promoting dry eye therapy in China, it is both safe and effective, and can significantly enhance the baseline tear secretion level.[1], applicable for improving dry eye symptoms in adult patients, offering a new treatment option for those with dry eye.
2017"International Dry Eye Guideline, Second Edition"(TFOS DEWS II) Includes Nasal Nerve Stimulation in Recommended Treatments for Dry Eye Syndrome[2]In 2020, the iTEAR, which adopts external nasal nerve stimulation for the treatment of dry eye®100 has successfully obtained FDA (U.S. Food and Drug Administration) approval in the United States, isThe first nasal extraneural stimulation device approved by the FDA for the treatment of dry eye disease，Meanwhile, the upgraded version of iTEAR Muqing®Also officially upgraded and launched in China on May 14.
iTEAR Muqing®：
Revolutionary Technology Opens a New Era in Natural Tear Dry Eye Treatment
Dry eye is a common chronic ocular surface disease caused by various factors, seriously affecting patients' daily lives. In recent years, due to the widespread use of screen terminal devices and other factors, the incidence of dry eye has been increasing year by year. Data shows that the incidence of dry eye in Asia ranks among the highest globally, with the incidence rate in China being approximately 21%-30%.[3]Dry eye is increasingly recognized as a serious public health issue and has become one of the most common reasons for people seeking eye care.
One of the main core factors in the pathogenesis of dry eye is tear film instability, and restoring tear film homeostasis is the primary treatment goal for dry eye. Therefore, existing dry eye treatments are mainly divided into targeted supplementation or repair of certain components of the tear film and regulation of natural tear secretion. For example, artificial tears that emphasize aqueous supplementation, physical treatments targeting the lipid layer such as meibomian gland warm compresses, massage, and intense pulsed light therapy. However, the rich composition of natural tears is difficult to replace, and due to the diversity of dry eye, a significant number of patients are dissatisfied with the effectiveness of existing treatments.[4]。
In response to this, iTEAR Muqing®AdoptNew Mechanism, stimulating natural tear secretion through external nasal nerve stimulation,Simple operation, non-invasive, portable, and safe with mild adverse reactions.. More importantly, the human body's ownNatural tears are rich in components and have comprehensive functions, which artificial tears cannot replace., while iTEAR Mu Qin®The uniqueness lies in its ability toWhile promoting the secretion of natural tears containing water, lipids, and mucin, it comprehensively improves the symptoms and signs of dry eye.[5-7]. In addition, using iTEAR Soothing®It can effectively reduce the dependence on artificial tears, bringing good news to a large number of dry eye patients.[1]。
In2024 China Corneal Disease Forum & The 23rd National Corneal and Ocular Surface Diseases Academic ConferenceAbove, Eye, Ear, Nose and Throat Hospital of Fudan UniversityProfessor Gong Lan shared the latest clinical researchNew Choice for Dry Eye Patients —— Nasal Nerve Stimulation Promotes Physiological Tear Secretion, Clinical Relevant Data Shows That iTEAR Muqing...®Rapid onset of action after stimulation, with significant increases in patients' baseline tear secretion, immediate tear secretion, and tear meniscus height, enablingRapidHelp restore tear film stability in dry eye patients, significantly improve dry eye symptoms and signs, and bring a new treatment option to dry eye patients. Professor Gong Lan expressed that she looks forward to this new mechanism-based dry eye therapy benefiting a large number of dry eye patients.
iTEAR Mu Qin®The emergence of the self-tear secretion stimulator marks a new era in the field of dry eye treatment, utilizing external nasal nerve stimulation to promote natural tear production.
iTEAR Muqin®：
Crafted with Ingenuity, Cross-Boundary Excellence
External Nasal Nerve Stimulation for Dry Eye Therapy has been approved as a medical device in both China and the United States, with the upgraded version iTEAR Muqing.®The self-tear secretion device, iTEAR Muqing, has been meticulously co-designed by Arctic Vision in collaboration with the internationally renowned design firm, frog design. It aims to enhance user experience across multiple dimensions, including sensory touch, grip angle, and portability.®We hope that users can comfortably experience "the natural tears of joy" while enjoying the benefits brought by dry eye treatment.
In order to let everyone more intuitively understand iTEAR Muqing®For the usage and effects, Arctic Vison has specially produced a detailed instructional video for reference. Everyone is also welcome to follow Arctic Vison's official channels to obtain more information.
Usage:Place the probe of the handheld device on the skin between the nasal cartilage and the nasal bone for use.
Frequency of use:Twice Daily, each time respectively on each sideStimulate for 30 Seconds。
Mechanism of Action:Vibration stimulates the external nasal branch of the anterior ethmoidal nerve, triggering natural tear secretion.
Effect of use:
-Immediate Effect, tear secretion after useReal-timeEnhance3.7 times。
-30 DaysSignificant Increase in Basal Tear Secretion57%, promote the recovery of the ability to secrete tears naturally.
- Slow down the evaporation of tears and effectively enhance the stability of the tear film.（TBUT＋34%）, improve the signs and symptoms of dry eye for long-term benefits.[1]
Dr. Hu Haidi, Founder, Chairman and Chief Executive Officer of Arctic Vison, said:
"Delighted to introduce the new generation of iTEAR Muqing"®The Self-tear Secretion Stimulator iTEAR Upgrades and Sets Sail in China. Facing a large number of dry eye patients with complex causes in China, we look forward to iTEAR Muqing.®"Arctic Vision is committed to bringing breakthrough ophthalmic innovations and therapies to patients and consumers in China, Asia, and around the world. With a rich product pipeline, we will maintain close industry-academia-research cooperation with our partners to accelerate the delivery of more innovative ophthalmic treatments. These therapies not only provide convenient and effective relief for dry eye symptoms but also update existing dry eye management models. In the future, we aim to help more Chinese patients improve their quality of life and contribute to the realization of the Healthy China 2030 goals."
About Arctic Vison
Arctic Vision is a biotechnology company headquartered in China, focusing on innovative ophthalmic therapies. It has a portfolio of breakthrough ophthalmic treatment technologies covering stages from early discovery to commercialization. The company’s vision is to address unmet clinical needs in the field of ophthalmic diseases by providing innovative therapies in China, Asia, and globally, benefiting a wide range of patients with eye conditions. Arctic Vision was founded with the support of professional investment firms in the life sciences sector and is managed by an elite team with extensive experience in global ophthalmic product development and commercialization. For more information, please visit www.arcticvision.com.
Currently iTEAR Muqing®—Autologous Tear Secretion Stimulator (Class II Medical Device) is now open for enthusiastic business cooperation! Scan the QR code below to partner with Arctic Vision and jointly explore the new market for dry eye treatment!
Scan the QR code to learn about investment opportunities.
References:
1. Marco H, Ji,Darius M, Moshfeghi,Laura, Periman et al. Novel Extranasal Tear Stimulation: Pivotal Study Results.[J] .Transl Vis Sci Technol, 2020, 9: 0.
2. Lyndon, Jones,Laura E, Downie,Donald, Korb et al. TFOS DEWS II Management and Therapy Report.[J] .Ocul Surf, 2017, 15: 0.
3. Corneal Disease Group of Ophthalmology Branch of Chinese Medical Association. Expert consensus on clinical diagnosis and treatment of dry eye (2013) [J]. Chinese Journal of Ophthalmology, 2013, 49(1):3.
4. Gong Lan, Wang Wushuang. New Therapy for Dry Eye: Nerve Stimulation Promotes Natural Tear Secretion[J]. Chinese Journal of Experimental Ophthalmology, 2024, 42(4):305-308.
5. Abhirup, Mandal,Vrinda, Gote,Dhananjay, Pal et al. Ocular Pharmacokinetics of a Topical Ophthalmic Nanomicellar Solution of Cyclosporine (Cequa®) for Dry Eye Disease.[J] .Pharm Res, 2019, 36: 0.
6. Garrett, Jones,Tae Jin, Lee,Joshua, Glass et al. Comparison of Different Mass Spectrometry Workflows for the Proteomic Analysis of Tear Fluid.[J] .Int J Mol Sci, 2022, 23: 0.
7. Sin Man, Lam,Louis, Tong,Xinrui, Duan et al. Extensive characterization of human tear fluid collected using different techniques unravels the presence of novel lipid amphiphiles.[J] .J Lipid Res, 2013, 55: 0.
This material aims to convey cutting-edge pharmaceutical information and research progress, and is not intended for advertising purposes. The information contained in this material is for reference only; please follow the advice or guidance of doctors or other healthcare professionals.
Disclaimer: This article is intended solely for academic exchange among healthcare professionals and does not represent the views of this platform. Such information cannot replace professional medical guidance in any way and should not be considered as diagnostic or therapeutic advice. If this information is used for purposes other than reference, this platform and the author assume no responsibility.